Last reviewed · How we verify
Budesonide nasal wash
At a glance
| Generic name | Budesonide nasal wash |
|---|---|
| Also known as | pulmicort |
| Sponsor | Kafrelsheikh University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis (PHASE4)
- Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity (PHASE3)
- Nebulized Nasal Steroids (PHASE1, PHASE2)
- Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19) (PHASE4)
- Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis (PHASE4)
- Budesonide Nasal Irrigation Versus Fluticasone Propionate Nasal Spray in Treating Allergic Rhinitis Patients (PHASE4)
- The Effect of Modified Olfactory Training on Postoperative Olfactory Dysfunction in Patients With CRS (NA)
- Budesonide Irrigation in Allergic Rhinitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide nasal wash CI brief — competitive landscape report
- Budesonide nasal wash updates RSS · CI watch RSS
- Kafrelsheikh University portfolio CI